Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Satellite Stem Cells and Muscular Dystrophy01:21

Satellite Stem Cells and Muscular Dystrophy

2.5K
Satellite stem cells or myosatellite cells are quiescent stem cells that Alexander Mauro first identified in 1961. These cells are located between the sarcolemma, the plasma membrane of muscle fibers, and the basal lamina, the connective tissue sheath covering it. These mononucleated cells are activated in response to muscle injury, can transform into myoblasts, and may form or repair muscle fibers. Myosatellite cells can provide additional myonuclei for muscle regeneration or return to a...
2.5K
Myasthenia Gravis: Overview and Treatment01:20

Myasthenia Gravis: Overview and Treatment

3.1K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
3.1K
Skeletal Muscle Relaxants: Therapeutic Uses01:31

Skeletal Muscle Relaxants: Therapeutic Uses

1.1K
Skeletal muscle relaxants are used to relax muscle tone and alleviate painful muscle contractions. However, the choice of skeletal muscle relaxants depends on the duration of the surgical procedure in order to minimize potential side effects. Skeletal muscle relaxants like neuromuscular blocking agents [NMBAs] are commonly employed as adjuvants alongside general anesthetics in clinical settings. NMBAs are also used to maintain controlled ventilation during surgery of the larynx or pharynx...
1.1K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Systemic Inflammation Modulates Clearance and Drives Extra-Hepatic Distribution of Extracellular Vesicles.

Journal of extracellular vesicles·2026
Same author

Myonuclear Domain-Associated and Central Nucleation-Dependent Spatial Restriction of Dystrophin Protein Expression.

Journal of cachexia, sarcopenia and muscle·2026
Same author

Design, validation, and functional impact of oligonucleotides for multigene silencing in Alzheimer's disease.

Molecular therapy. Nucleic acids·2026
Same author

Biophysical and biological properties of splice-switching oligonucleotides and click conjugates containing LNA-phosphothiotriester linkages.

Nucleic acids research·2025
Same author

Synthesis, Biological Activity, and Molecular Dynamics Simulations of LNA-Charge Neutral Linkages for Enhanced Splice-Switching Antisense Oligonucleotides.

Angewandte Chemie (International ed. in English)·2025
Same author

AAV microdystrophin gene replacement therapy for Duchenne muscular dystrophy: progress and prospects.

Gene therapy·2025

Related Experiment Video

Updated: Feb 28, 2026

Evaluation of Exon Inclusion Induced by Splice Switching Antisense Oligonucleotides in SMA Patient Fibroblasts
07:02

Evaluation of Exon Inclusion Induced by Splice Switching Antisense Oligonucleotides in SMA Patient Fibroblasts

Published on: May 11, 2018

14.5K

Splice-Switching Therapy for Spinal Muscular Atrophy.

Katharina E Meijboom1, Matthew J A Wood2, Graham McClorey3

  • 1Department of Physiology, Anatomy and Genetics, University of Oxford, South Parks Road, Oxford OX1 3QX, UK. karin.meijboom@dpag.ox.ac.uk.

Genes
|June 13, 2017
PubMed
Summary
This summary is machine-generated.

Spinal muscular atrophy (SMA) therapy enhances SMN protein production via exon inclusion. This approach offers new hope for patients, though limitations and alternative genetic strategies are also discussed.

Keywords:
clinical trialsspinal muscular atrophysplice-switching oligonucleotides

More Related Videos

Delivery of Therapeutic Agents Through Intracerebroventricular ICV and Intravenous IV Injection in Mice
05:55

Delivery of Therapeutic Agents Through Intracerebroventricular ICV and Intravenous IV Injection in Mice

Published on: October 3, 2011

63.6K
Direct Reprogramming of Human Fibroblasts into Myoblasts to Investigate Therapies for Neuromuscular Disorders
10:28

Direct Reprogramming of Human Fibroblasts into Myoblasts to Investigate Therapies for Neuromuscular Disorders

Published on: April 3, 2021

7.2K

Related Experiment Videos

Last Updated: Feb 28, 2026

Evaluation of Exon Inclusion Induced by Splice Switching Antisense Oligonucleotides in SMA Patient Fibroblasts
07:02

Evaluation of Exon Inclusion Induced by Splice Switching Antisense Oligonucleotides in SMA Patient Fibroblasts

Published on: May 11, 2018

14.5K
Delivery of Therapeutic Agents Through Intracerebroventricular ICV and Intravenous IV Injection in Mice
05:55

Delivery of Therapeutic Agents Through Intracerebroventricular ICV and Intravenous IV Injection in Mice

Published on: October 3, 2011

63.6K
Direct Reprogramming of Human Fibroblasts into Myoblasts to Investigate Therapies for Neuromuscular Disorders
10:28

Direct Reprogramming of Human Fibroblasts into Myoblasts to Investigate Therapies for Neuromuscular Disorders

Published on: April 3, 2021

7.2K

Area of Science:

  • Genetics
  • Neurology
  • Molecular Biology

Background:

  • Spinal muscular atrophy (SMA) is a severe genetic neuromuscular disorder.
  • The genetic cause of SMA has been known for over two decades.
  • Recent advancements have led to the first approved therapy for severe SMA.

Purpose of the Study:

  • To discuss the genetic basis of Spinal Muscular Atrophy (SMA).
  • To review the development of splice-switching oligonucleotide therapy for SMA.
  • To explore limitations and alternative genetic strategies for SMA treatment.

Main Methods:

  • Review of genetic studies identifying the cause of SMA.
  • Explanation of splice-switching oligonucleotide (SSO) mechanism for exon inclusion.
  • Discussion of current clinical trials for alternative SMA therapies.

Main Results:

  • SSOs enhance the production of Survival Motor Neuron (SMN) protein in SMA patients.
  • Exon inclusion into mature mRNA is the key mechanism of SSO therapy.
  • Oligonucleotide-based therapies represent a significant therapeutic breakthrough for SMA.

Conclusions:

  • The approval of oligonucleotide therapies for SMA is a major milestone.
  • Limitations of current SSO therapies warrant further investigation.
  • Alternative genetic strategies are progressing through clinical trials for SMA.